An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.
Zainab K. SanusiThavendran GovenderGlenn E. M. MaguireSibusiso B. MasekoJohnson LinHendrik G. KrugerBahareh HonarparvarPublished in: J. Comput. Aided Mol. Des. (2018)